Tech Company Financing Transactions
Tivorsan Pharmaceuticals Funding Round
Tivorsan Pharmaceuticals, based in Providence, received $4.5 million from private investors.
Transaction Overview
Company Name
Announced On
10/26/2018
Transaction Type
Venture Equity
Amount
$4,474,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 32 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Davol Sq. A340
Providence, RI 02903
USA
Providence, RI 02903
USA
Phone
Website
Email Address
Overview
Tivorsan Pharmaceuticals is a protein therapeutics company pioneering a unique approach to treat serious neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
John Nicholson
Chief Executive Officer
Michael Meyers
Chief Scientific Officer
Justin Fallon
Browse more venture capital transactions:
Prev: 10/26/2018: Geltor venture capital transaction
Next: 10/26/2018: Tivorsan Pharmaceuticals venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs